Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS5 | Q9UNA0 | 9/20 | 0.64 |
| ▸ | BCHE | P06276 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3425867 | 0.93 | BCHE (0.63) | ADAMTS5BCHEMAPTKMT2A | |
| SCHEMBL3426065 | 0.86 | KMT2A (0.57) | ADAMTS5MAPTKMT2A | |
| SCHEMBL25184682 | 0.80 | ALOX12 (0.70) | ADAMTS5BCHEMAPTKMT2A | |
| SCHEMBL3427560 | 0.79 | GAA (0.60) | MAPTKMT2A | |
| SCHEMBL17894552 | 0.78 | BCHE (0.63) | BCHEMAPTKMT2A | |
| Hydrochloric Acid SCHEMBL8202366 | 0.77 | MRGPRX1 (0.61) | BCHEMAPTKMT2A | |
| SCHEMBL4506574 | 0.76 | LMNA (0.78) | BCHEFFAR1GSTP1MAPTKMT2A | |
| SCHEMBL133802 | 0.76 | ALOX12 (0.68) | MAPTKMT2A | |
| SCHEMBL23665904 | 0.76 | GSTP1 (0.68) | BCHEFFAR1GSTP1MAPT | |
| SCHEMBL23483029 | 0.76 | LMNA (0.69) | BCHEFFAR1GSTP1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | claimed |
| CN-1849301-A | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS INC (US) | 2006-10-18 | — | — | CN | claimed |
| EP-1648862-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | Achillion Pharmaceuticals, Inc. (US) | 2006-04-26 | — | — | EP | claimed |
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | claimed |
| WO-2005007601-A2 | SUBSTITUTED ARYLTHIOUREA DERIVATIVES USEFUL AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | claimed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-7718671-B2 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032849-A1 | Substituted arylthiourea derivatives useful as inhibitors of viral replication | TPMT, NAT1, GOT1 | ADAMTS5 3520/4885BCHE 2692/4885FFAR1 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.